Boyd Watterson Asset Management LLC OH Cuts Position in Becton, Dickinson and Company (NYSE:BDX)

Boyd Watterson Asset Management LLC OH reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 58.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 106 shares of the medical instruments supplier’s stock after selling 150 shares during the period. Boyd Watterson Asset Management LLC OH’s holdings in Becton, Dickinson and Company were worth $26,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Jennison Associates LLC raised its holdings in Becton, Dickinson and Company by 4.9% during the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after purchasing an additional 18,786 shares during the last quarter. Norden Group LLC increased its stake in shares of Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after acquiring an additional 49,559 shares during the last quarter. Avity Investment Management Inc. increased its stake in shares of Becton, Dickinson and Company by 3.5% during the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after acquiring an additional 5,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Becton, Dickinson and Company by 9.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock worth $14,481,000 after acquiring an additional 5,006 shares during the period. Finally, Axxcess Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 30.2% in the first quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock worth $2,735,000 after acquiring an additional 2,565 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BDX shares. Stifel Nicolaus upped their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Raymond James decreased their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Trading Up 0.3 %

NYSE:BDX opened at $240.52 on Thursday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $262.23. The firm has a market capitalization of $69.51 billion, a P/E ratio of 52.98, a P/E/G ratio of 1.79 and a beta of 0.42. The business has a 50 day simple moving average of $237.33 and a 200 day simple moving average of $235.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the prior year, the firm posted $2.96 earnings per share. The company’s revenue was up 2.3% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post 13.11 EPS for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.